Literature DB >> 20579229

Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility.

Gilles Gavaudan1, David Magalon, Julien Cohen, Christophe Lançon, Georges Léonetti, Anne-Laure Pélissier-Alicot.   

Abstract

Pathological gambling (PG), classified in the DSM-IV among impulse control disorders, is defined as inappropriate, persistent gaming for money with serious personal, family, and social consequences. Offenses are frequently committed to obtain money for gambling. Pathological gambling, a planned and structured behavioral disorder, has often been described as a complication of dopamine agonist treatment in patients with Parkinson's disease. It has never been described in patients with schizophrenia receiving dopamine agonists. We present two patients with schizophrenia, previously treated with antipsychotic drugs without any suggestion of PG, who a short time after starting aripiprazole, a dopamine partial agonist, developed PG and criminal behavior, which totally resolved when aripiprazole was discontinued. Based on recent advances in research on PG and adverse drug reactions to dopamine agonists in Parkinson's disease, we postulate a link between aripiprazole and PG in both our patients with schizophrenia and raise the question of criminal responsibility.
© 2010 American Academy of Forensic Sciences.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20579229     DOI: 10.1111/j.1556-4029.2010.01483.x

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  2 in total

1.  Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System.

Authors:  Cristina Scavone; Barbara Stelitano; Concetta Rafaniello; Francesco Rossi; Liberata Sportiello; Annalisa Capuano
Journal:  J Gambl Stud       Date:  2020-03

Review 2.  Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review.

Authors:  Marie Grall-Bronnec; Anne Sauvaget; Fanny Perrouin; Juliette Leboucher; François Etcheverrigaray; Gaëlle Challet-Bouju; Louise Gaboriau; Pascal Derkinderen; Pascale Jolliet; Caroline Victorri-Vigneau
Journal:  J Clin Psychopharmacol       Date:  2016-02       Impact factor: 3.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.